638 completed, 207 recruiting, 167 unknown, 102 terminated. 312 Phase 2, 263 Phase 3, 141 Phase 1, 123 Not applicable, 94 Phase 4.
Follow Skin Diseases, Vascular: new trials by email Literature Review of Skin Diseases, Vascular trials Research Report on Skin Diseases, Vascular
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases CD19-targeted iNKT Cell Injection - IgA Nephropathy (IgAN), Membranous Nephropathy | Early Phase 1 | Not yet recruiting | Grit Biotechnology | 30 | 2027-08-01 | 2026-09-11 |
| Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's Disease BOTOX INJECTION - Buerger Disease, Raynaud Syndrome | Phase 3 | Not yet recruiting | University Hospital, Toulouse | 8 | 2027-01-01 | 2026-07-23 |
| Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study. [18F]FDG Long-Axial Field of View (LAFOV)-PET/CT, CT Angiogram, MR Angiogram - Large Vessel Vasculitis, Takayasu Arteritis | Not applicable | Not yet recruiting | Imperial College London | 18 | 2026-12-01 | 2026-10-16 |
| A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt No intervention - Hereditary Angioedema (HAE) | Not yet recruiting | Takeda | 100 | 2026-12-01 | 2026-06-18 | |
| Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Not yet recruiting | Peking University Third Hospital | 9 | 2026-11-01 | 2026-09-23 |
| Emerging Indications for Hyperbaric Oxygen Treatment Hyperbaric oxygen treatment (HBOT), 100% Oxygen - Post-COVID-19 Condition, Ulcerative Colitis | Phase 4 | Not yet recruiting | Jay C. Buckey Jr. | 100 | 2026-11-01 | 2026-09-09 |
| Efficacy and Safety of Immunoglobulin Plus Firsekibart in Patients With Kawasaki Disease IVIG, Aspirin, Firsekibart - Kawasaki Disease | Phase 2 / Phase 3 | Not yet recruiting | Children's Hospital of Fudan University | 90 | 2026-11-01 | 2026-10-22 |
| A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon Attacks LIQ861 (treprostinil) inhalation powder - Dose Titration Arm, LIQ861 (treprostinil) inhalation powder - fixed dose arm - Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Not yet recruiting | Liquidia Technologies, Inc. | 75 | 2026-10-26 | 2026-08-07 |
| A Trial to Evaluate the Efficacy and Safety of AK139 in Participants With Chronic Spontaneous Urticaria AK139, Placebo - Chronic Spontaneous Urticaria | Phase 2 | Not yet recruiting | Akeso | 201 | 2026-10-21 | 2026-10-15 |
| Qualitative Study With Focus Groups of People Living With ANCA-associated Vasculitis (AAV) and Clinicians, to Explore Different Perspectives on Shared Decision-making in AAV. ANCA Associated Vasculitis (AAV) | Not yet recruiting | University of the West of England | 80 | 2026-10-01 | 2026-10-06 | |
| Mapping B-cell Biology Across the Cardiovascular Territories of Giant Cell Arteritis: Towards a New Therapeutic Approach (RituxiMAP GCA) Zirconium Zr 89 labelled rituximab - Giant Cell Arteritis (GCA) | Not yet recruiting | University of Edinburgh | 30 | 2026-10-01 | 2026-06-16 | |
| FT839 in Autoimmune Diseases FT839 - ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 / Phase 2 | Recruiting | Fate Therapeutics | 446 | 2026-10-01 | 2026-09-02 |
| Clinical, Laboratory, and Therapeutic Analysis of Behçet's Disease in Assiut Behçet's Disease | Not yet recruiting | Assiut University | 30 | 2026-09-30 | 2025-09-05 | |
| Serum EBI-3 Protein Levels in Behçet's Disease Behçet Disease | Not yet recruiting | Assiut University | 90 | 2026-09-26 | 2026-09-28 | |
| A Phase 2 Study of MG-K10 in Chronic Spontaneous Urticaria MG-K10 Injection, Matching Placebo - Chronic Urticaria, Idiopathic | Phase 2 | Not yet recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 60 | 2026-09-23 | 2026-09-24 |
| Apremilast Added to Antihistamines in Chronic Urticaria Apremilast, Second-generation H1 antihistamine - Chronic Urticaria, Chronic Spontaneous Urticaria | Phase 2 | Enrolling by invitation | Rashid Latif Medical College | 86 | 2026-09-23 | 2026-09-30 |
| Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks Remibrutinib, Omalizumab - Chronic Spontaneous Urticaria | Phase 3 | Recruiting | Novartis Pharmaceuticals | 382 | 2026-09-21 | 2026-10-13 |
| A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea No intervention - Hereditary Angioedema (HAE) | Recruiting | Takeda | 35 | 2026-09-21 | 2026-10-15 | |
| A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHs TLL-018 tablets, Placebo - Chronic Spontaneous Urticaria (CSU) | Phase 2 | Not yet recruiting | Hangzhou Highlightll Pharmaceutical Co., Ltd | 140 | 2026-09-10 | 2026-08-24 |
| Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research Pericarditis, Tako-TSUBO Cardiomyopathy | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 300 | 2026-09-01 | 2026-08-10 |
Showing 20 of 1296. Sign in to see all of them.
Chronic Urticaria (191) · Angioedemas, Hereditary (169) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (153) · Giant Cell Arteritis (145) · Urticaria (133) · Behcet Syndrome (131) · Granulomatosis with Polyangiitis (104) · Vasculitis (91) · Raynaud Disease (80) · Takayasu Arteritis (76) · Scleroderma, Systemic (73) · Microscopic Polyangiitis (69) · Angioedema (64) · Mucocutaneous Lymph Node Syndrome (62) · Churg-Strauss Syndrome (61)
Skin and Connective Tissue Diseases (1296) · Skin Diseases (1280) · Immune System Diseases (964) · Vascular Diseases (936) · Cardiovascular Diseases (934) · Hypersensitivity (561) · Vasculitis (558) · Hypersensitivity, Immediate (534) · Autoimmune Diseases (400) · Urticaria (395) · Pathological Conditions, Signs and Symptoms (377) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (368) · Genetic Diseases, Inborn (354) · Pathologic Processes (351)
Omalizumab (44) · Rituximab (41) · Cyclophosphamide (36) · Prednisone (33) · Complement C1 Inhibitor Protein (28) · tocilizumab (24) · Azathioprine (22) · Blood Specimen Collection (21) · Infliximab (19) · Glucocorticoids (18) · desloratadine (18) · canakinumab (17) · Methotrexate (16) · Prednisolone (16) · mepolizumab (16)
Novartis Pharmaceuticals (58) · Assistance Publique - Hôpitaux de Paris (51) · Shire (40) · National Institute of Allergy and Infectious Diseases (NIAID) (22) · Takeda (20) · Assiut University (18) · Charite University, Berlin, Germany (18) · University of Pennsylvania (18) · BioCryst Pharmaceuticals (17) · CSL Behring (15) · University Hospital, Grenoble (15) · Amgen (14) · Children's Hospital of Fudan University (13) · KalVista Pharmaceuticals, Ltd. (13) · Genentech, Inc. (11)
United States (421) · France (247) · Germany (215) · China (173) · Canada (154) · United Kingdom (154) · Italy (122) · Spain (116) · Poland (91) · Japan (77) · Netherlands (77) · Turkey (Türkiye) (77) · Australia (73) · Hungary (65) · Israel (58)
Peter A. Merkel, MD, MPH (13) · Peter A Merkel, MD, MPH (9) · Marcus Maurer, MD (7) · Lindi Jiang, PhD (6) · Fang Liu, MD (5) · Anurag Relan, MD (4)
PMID 36326435, PMID 36408587, PMID 36853224, PMID 20818886, PMID 23312695, PMID 23878046, PMID 24712435, PMID 33164993, PMID 37929840, PMID 23548529, PMID 26054553, PMID 27424128, PMID 27540466, PMID 27939380, PMID 28390587, PMID 28514601, PMID 29655772, PMID 42159953, PMID 42268494, PMID 17021840, PMID 20818888, PMID 20819318, PMID 20920772, PMID 21130380, PMID 22765833, PMID 22856635, PMID 23484892, PMID 23548526, PMID 23987198, PMID 25104279, PMID 25153486, PMID 25198193, PMID 25372085, PMID 26952547, PMID 28284978, PMID 28592297, PMID 28745999, PMID 31161734, PMID 31719529, PMID 32866179, PMID 33001543, PMID 33596356, PMID 34061144, PMID 34347947, PMID 34773261, PMID 35612893, PMID 35850947, PMID 36153561, PMID 36440464, PMID 36774155
2023 (16), 2019 (14), 2018 (13), U54AR057319 (12), 2014 (8), 2015 (7), 2009 (6), 2016 (6), 2017 (6), 2025 (6), 2008 (3), P01DK058335 (3), 2004 (2), R01HL115041 (2), 2005 (1)